BGLC BioNexus Gene Lab Corp

  1. Stocks
  2. Basic Materials
  3. NASDAQ: BGLC

Price (delayed)

$1.59

Market cap

$4.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.26

Enterprise value

$3.75M

?
Relative Growth: Rel. Growth: 16
Relative Strength: Rel. Strength: 5
Relative Valuation: Rel. Valuation: 25
Relative Profitability: Rel. Profitability: 15

BioNexus Gene Lab Corp. is an emerging Biotech company and a leading supplier of chemical raw materials in Southeast Asia. Through its subsidiaries, BGLC operates in the Biotech and Chemical ...

Highlights
The EPS has grown by 23% YoY and by 15% from the previous quarter
The net income has grown by 12% YoY and by 11% from the previous quarter
The quick ratio has soared by 56% year-on-year but it has declined by 13% since the previous quarter
The debt has surged by 52% year-on-year but it has declined by 7% since the previous quarter
BioNexus Gene Lab's gross profit has shrunk by 84% YoY
The gross margin has dropped by 72% year-on-year
Sector: Basic Materials
Industry: Specialty Chemicals
Website: https://www.bionexusgenelab.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of BGLC

BGLC stock price

How has the BioNexus Gene Lab stock price performed over time
Intraday
0.22%
1 week
1.27%
1 month
-2.45%
1 year
-72.2%
YTD
-59.75%
QTD
-18.46%

Financial performance

How have BioNexus Gene Lab's revenue and profit performed over time
Revenue
$3.03M
Gross profit
$397,334
Operating income
-$2.86M
Net income
-$2.58M
Gross margin
13.1%
Net margin
-85.1%
BioNexus Gene Lab's gross profit has shrunk by 84% YoY
The gross margin has dropped by 72% year-on-year
The net margin has declined by 50% year-on-year but it has grown by 11% since the previous quarter
BioNexus Gene Lab's operating margin has decreased by 45% YoY but it has increased by 21% QoQ

Price vs fundamentals

How does BGLC's price correlate with its fundamentals

Growth

What is BioNexus Gene Lab's growth rate over time

Valuation

What is BioNexus Gene Lab stock price valuation
P/E
N/A
P/B
0.49
P/S
1.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.24
The EPS has grown by 23% YoY and by 15% from the previous quarter
The P/B is 39% lower than the last 4 quarters average of 0.8
BioNexus Gene Lab's equity has decreased by 3.9% QoQ but it has increased by 3.4% YoY
The revenue has declined by 41% year-on-year
BGLC's price to sales (P/S) is 21% less than its last 4 quarters average of 1.6

Efficiency

How efficient is BioNexus Gene Lab business performance
The ROS has contracted by 46% YoY but it has grown by 11% from the previous quarter
The return on equity rose by 12% since the previous quarter and by 7% year-on-year
The return on invested capital has increased by 11% since the previous quarter and by 8% year-on-year
The ROA rose by 10% QoQ but it fell by 2.1% YoY

Dividends

What is BGLC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BGLC.

Financial health

How did BioNexus Gene Lab financials performed over time
BioNexus Gene Lab's current ratio has soared by 67% YoY but it has decreased by 7% from the previous quarter
The quick ratio has soared by 56% year-on-year but it has declined by 13% since the previous quarter
The debt is 96% smaller than the equity
The debt has surged by 52% year-on-year but it has declined by 7% since the previous quarter
The company's debt to equity rose by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.